Clinical Study
REVOLUTIONARY PRODUCT for CHRONIC KIDNEY DISEASE
IS THERE AN ORALLY CONSUMABLE PRODUCT USEFUL FOR DECREASING SERUM CREATININE LEVEL, DECREASE IN BLOOD UREA NITROGEN, INCREASING eGLOMARULAR FILTRATION RATE AND IMPROVEMENT IN QUALITY OF LIFE IN CHRONIC KIDNEY DISEASE PATIENTS?
YES. The first orally consumable product for CHRONIC KIDNEY DISEASE is now patented in Europe (EP3247323) and is now available;
FOR EXCLUSIVE SUB-LICENSING OF PATENT RIGHTS OR MARKETING RIGHTS to LEADING SMALL/BIG HEATHCARE COMPANIES for ENTIRE EUROPE or FOR INDIVIDUAL COUNTRIES IN EUROPE
